Contact | Print version | PDF version | Send article | RSS feed

Chemokine Therapeutics Receives Approval From Hong Kong to Commence Phase II Study in Liver Cancer

25 Aug 2008 - Chemokine Therapeutics Corp. announced that it has received a Certificate for Clinical Trial/Medicinal Test from the Hong Kong Department of Health allowing the Company to begin a Phase II trial in liver cancer with its lead drug candidate, CTCE-9908. The Company received FDA and Health Canada approval for the clinical trial earlier this year.
 
The Phase II trial will be an international, multi-centre, randomized, controlled, open label study assessing the efficacy and safety of CTCE-9908 that will include up to 132 patients with liver cancer.
 
"Liver cancer is more prevalent in the Asian communities and working with Dr. Ronnie Poon, Principal Investigator for Hong Kong, will help to expedite the patient recruitment process," stated Walter Korz, President and Chief Executive Officer of the Company.